Proportion of ulnar nerves with sensory improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with sensory improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in motor score after one year · patients with nerve damage in leprosy
1 finding from 1 review
Proportion of ulnar nerves with motor improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with motor improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in sensory score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Change in motor score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Disease severity as measured by patient‐reported symptom score (total nasal symptom score) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids probably leads to lower need for mechanical ventilation at 1 month compared with no such treatment (moderate certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Histological improvement (continuous) · inactive EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review